| 1 | A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker testsBrain, 2025, 148, 416-431 | 8.9 | 2 | Citations (PDF) |
| 2 | Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer’s disease model mice | 8.5 | 0 | Citations (PDF) |
| 3 | Combined Connectomics, <scp><i>MAPT</i></scp> Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease | 6.6 | 3 | Citations (PDF) |
| 4 | Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulationBrain, 2024, 147, 949-960 | 8.9 | 9 | Citations (PDF) |
| 5 | Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s diseaseBrain, 2024, 147, 961-969 | 8.9 | 4 | Citations (PDF) |
| 6 | Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests | 25.6 | 92 | Citations (PDF) |
| 7 | Biomarker-based staging of Alzheimer disease: rationale and clinical applications | 9.2 | 33 | Citations (PDF) |
| 8 | A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings | 14.1 | 5 | Citations (PDF) |
| 9 | Disease staging of Alzheimer’s disease using a CSF-based biomarker model | 8.5 | 17 | Citations (PDF) |
| 10 | MRI-Derived AD Signature of Cortical Thinning and Plasma P-Tau217 for Predicting Alzheimer Dementia Among Community-Dwelling Older Adults | 2.1 | 0 | Citations (PDF) |
| 11 | A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settingsBrain, 2024, 147, 2400-2413 | 8.9 | 4 | Citations (PDF) |
| 12 | Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases | 14.1 | 6 | Citations (PDF) |
| 13 | Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity | 1.3 | 0 | Citations (PDF) |
| 14 | Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease | 9.2 | 28 | Citations (PDF) |
| 15 | Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology | 14.1 | 8 | Citations (PDF) |
| 16 | Head‐to‐Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study | 6.6 | 1 | Citations (PDF) |
| 17 | Revised criteria for the diagnosis and staging of Alzheimer’s disease | 25.6 | 19 | Citations (PDF) |
| 18 | A clinical perspective on the revised criteria for diagnosis and staging of Alzheimer’s disease | 8.5 | 4 | Citations (PDF) |
| 19 | Proteomic changes in Alzheimer’s disease associated with progressive Aβ plaque and tau tangle pathologies | 12.4 | 8 | Citations (PDF) |
| 20 | Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease | 14.1 | 1 | Citations (PDF) |
| 21 | Test‐retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models | 0.7 | 30 | Citations (PDF) |
| 22 | Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individualsBrain, 2023, 146, 1580-1591 | 8.9 | 26 | Citations (PDF) |
| 23 | Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s diseaseBrain, 2023, 146, 1592-1601 | 8.9 | 206 | Citations (PDF) |
| 24 | Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s diseaseBrain, 2023, 146, 1602-1614 | 8.9 | 20 | Citations (PDF) |
| 25 | The genetic regulation of protein expression in cerebrospinal fluid | 7.2 | 20 | Citations (PDF) |
| 26 | Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi‐cohort study | 0.7 | 21 | Citations (PDF) |
| 27 | Plasma amyloid-β42/40 and <i>APOE</i> for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease | 3.8 | 6 | Citations (PDF) |
| 28 | Polygenic risk of type 2 diabetes is associated with incident vascular dementia: a prospective cohort study | 3.8 | 6 | Citations (PDF) |
| 29 | Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease | 3.8 | 29 | Citations (PDF) |
| 30 | Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads | 7.2 | 77 | Citations (PDF) |
| 31 | CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease | 8.5 | 58 | Citations (PDF) |
| 32 | Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysisBrain, 2023, 146, 3719-3734 | 8.9 | 14 | Citations (PDF) |
| 33 | Ultra-high field imaging, plasma markers and autopsy data uncover a specific rostral locus coeruleus vulnerability to hyperphosphorylated tau | 8.3 | 11 | Citations (PDF) |
| 34 | Age-related and amyloid-beta-independent tau deposition and its downstream effectsBrain, 2023, 146, 3192-3205 | 8.9 | 26 | Citations (PDF) |
| 35 | Data-driven neuropathological staging and subtyping of TDP-43 proteinopathiesBrain, 2023, 146, 2975-2988 | 8.9 | 29 | Citations (PDF) |
| 36 | ‘Proactive aging’ is a new research approach for a new era | 8.5 | 2 | Citations (PDF) |
| 37 | Blood biomarkers for Alzheimer’s disease in clinical practice and trials | 8.5 | 121 | Citations (PDF) |
| 38 | CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease | 25.6 | 75 | Citations (PDF) |
| 39 | Cognitive effects of Lewy body pathology in clinically unimpaired individuals | 25.6 | 45 | Citations (PDF) |
| 40 | Clinical effects of Lewy body pathology in cognitively impaired individuals | 25.6 | 52 | Citations (PDF) |
| 41 | A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases | 8.5 | 64 | Citations (PDF) |
| 42 | DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease | 8.5 | 34 | Citations (PDF) |
| 43 | Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets | 13.1 | 220 | Citations (PDF) |
| 44 | Anterior cingulate sulcation is associated with onset and survival in frontotemporal dementia | 3.8 | 3 | Citations (PDF) |
| 45 | The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases | 14.1 | 37 | Citations (PDF) |
| 46 | Harnessing cognitive trajectory clusterings to examine subclinical decline risk factors | 3.8 | 1 | Citations (PDF) |
| 47 | Diffusion weighted magnetic resonance spectroscopy revealed neuronal specific microstructural alterations in Alzheimer’s disease | 3.8 | 0 | Citations (PDF) |
| 48 | The <i>BIN1</i> rs744373 Alzheimer's disease risk SNP is associated with faster Aβ‐associated tau accumulation and cognitive decline | 0.7 | 26 | Citations (PDF) |
| 49 | Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau | 0.7 | 109 | Citations (PDF) |
| 50 | Decreased pain sensitivity and alterations of cerebrospinal fluid and plasma inflammatory mediators after total hip arthroplasty in patients with disabling osteoarthritis | 2.1 | 5 | Citations (PDF) |
| 51 | Tau pathology mediates age effects on medial temporal lobe structure | 3.4 | 11 | Citations (PDF) |
| 52 | Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives | 2.7 | 15 | Citations (PDF) |
| 53 | Serum Neurofilament Light Chain as a Marker of Progression in Parkinson’s Disease: Long-Term Observation and Implications of Clinical Subtypes | 3.7 | 18 | Citations (PDF) |
| 54 | Blood-based biomarkers for Alzheimer's disease: towards clinical implementation | 19.1 | 493 | Citations (PDF) |
| 55 | Insights on Genetic and Environmental Factors in Parkinson’s Disease from a Regional Swedish Case-Control Cohort | 3.7 | 6 | Citations (PDF) |
| 56 | Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network | 2.7 | 2 | Citations (PDF) |
| 57 | Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group | 0.7 | 125 | Citations (PDF) |
| 58 | Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization | 2.5 | 9 | Citations (PDF) |
| 59 | Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum | 14.3 | 133 | Citations (PDF) |
| 60 | Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition | 1.3 | 28 | Citations (PDF) |
| 61 | Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels | 5.1 | 34 | Citations (PDF) |
| 62 | Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer’s Disease Pathology and Cognitive Decline | 1.7 | 35 | Citations (PDF) |
| 63 | Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings | 0.7 | 27 | Citations (PDF) |
| 64 | Components of gait in people with and without mild cognitive impairment | 1.2 | 13 | Citations (PDF) |
| 65 | Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention | 6.6 | 18 | Citations (PDF) |
| 66 | The accuracy and robustness of plasma biomarker models for amyloid PET positivity | 6.7 | 60 | Citations (PDF) |
| 67 | The Neuroinflammatory Acute Phase Response in Parkinsonian‐Related Disorders | 5.3 | 9 | Citations (PDF) |
| 68 | Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease | 14.3 | 88 | Citations (PDF) |
| 69 | Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration | 1.3 | 62 | Citations (PDF) |
| 70 | Subtypes of Alzheimer’s disease: questions, controversy, and meaning | 13.4 | 19 | Citations (PDF) |
| 71 | Midsagittal corpus callosal thickness and cognitive impairment in Parkinson's disease | 3.7 | 10 | Citations (PDF) |
| 72 | Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients | 6.7 | 28 | Citations (PDF) |
| 73 | The protective gene dose effect of the <i>APOE</i><i>ε2</i> allele on gray matter volume in cognitively unimpaired individuals | 0.7 | 16 | Citations (PDF) |
| 74 | Association of CSF Aβ
<sub>38</sub>
Levels With Risk of Alzheimer Disease–Related Decline | 1.3 | 24 | Citations (PDF) |
| 75 | Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques | 1.3 | 105 | Citations (PDF) |
| 76 | Blood‐based biomarkers for Alzheimer's disease | 7.2 | 176 | Citations (PDF) |
| 77 | Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217 | 6.7 | 29 | Citations (PDF) |
| 78 | Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials | 19.1 | 219 | Citations (PDF) |
| 79 | Astrocytic function is associated with both amyloid-β and tau pathology in non-demented<i>APOE ϵ4</i>carriers | 3.8 | 11 | Citations (PDF) |
| 80 | Tau PET Imaging in Neurodegenerative Disorders | 6.6 | 50 | Citations (PDF) |
| 81 | Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease | 5.1 | 62 | Citations (PDF) |
| 82 | Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers | 14.3 | 29 | Citations (PDF) |
| 83 | Comparison of risk factors for Parkinson’s disease, coronary events and ischemic stroke | 7.4 | 7 | Citations (PDF) |
| 84 | Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading | 14.1 | 33 | Citations (PDF) |
| 85 | Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline | 25.6 | 169 | Citations (PDF) |
| 86 | Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease | 14.1 | 54 | Citations (PDF) |
| 87 | Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology | 8.5 | 30 | Citations (PDF) |
| 88 | Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring | 25.6 | 166 | Citations (PDF) |
| 89 | Novel insights regarding the measurement properties of the SCOPA-AUT | 2.1 | 4 | Citations (PDF) |
| 90 | Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease | 1.3 | 63 | Citations (PDF) |
| 91 | The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People | 3.6 | 9 | Citations (PDF) |
| 92 | Acute phase markers in CSF reveal inflammatory changes in Alzheimer’s disease that intersect with pathology, APOE ε4, sex and age | 6.0 | 26 | Citations (PDF) |
| 93 | Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment | 14.3 | 38 | Citations (PDF) |
| 94 | Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease | 3.8 | 29 | Citations (PDF) |
| 95 | Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease | 5.3 | 47 | Citations (PDF) |
| 96 | Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s diseaseBrain, 2021, 144, 310-324 | 8.9 | 144 | Citations (PDF) |
| 97 | Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease | 14.3 | 215 | Citations (PDF) |
| 98 | SCRT1 is a novel beta cell transcription factor with insulin regulatory properties | 3.5 | 3 | Citations (PDF) |
| 99 | Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease | 4.1 | 64 | Citations (PDF) |
| 100 | Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s disease | 5.7 | 84 | Citations (PDF) |
| 101 | Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid, tau, and cognition | 3.7 | 33 | Citations (PDF) |
| 102 | Biomarker testing in MCI patients—deciding who to test | 6.7 | 6 | Citations (PDF) |
| 103 | Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers | 5.1 | 20 | Citations (PDF) |
| 104 | Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias | 6.7 | 11 | Citations (PDF) |
| 105 | Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework | 5.4 | 36 | Citations (PDF) |
| 106 | Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework | 5.4 | 37 | Citations (PDF) |
| 107 | Time between milestone events in the Alzheimer's disease amyloid cascade | 4.8 | 27 | Citations (PDF) |
| 108 | 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework | 5.4 | 48 | Citations (PDF) |
| 109 | The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau | 0.7 | 76 | Citations (PDF) |
| 110 | Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment | 6.7 | 165 | Citations (PDF) |
| 111 | The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers | 5.4 | 88 | Citations (PDF) |
| 112 | Early stages of tau pathology and its associations with functional connectivity, atrophy and memoryBrain, 2021, 144, 2771-2783 | 8.9 | 105 | Citations (PDF) |
| 113 | Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework | 5.4 | 10 | Citations (PDF) |
| 114 | The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update | 5.4 | 25 | Citations (PDF) |
| 115 | Four distinct trajectories of tau deposition identified in Alzheimer’s disease | 25.6 | 403 | Citations (PDF) |
| 116 | A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images | 5.4 | 23 | Citations (PDF) |
| 117 | Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s disease | 2.0 | 19 | Citations (PDF) |
| 118 | Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease‐modifying treatments—EQ‐5D data from the Swedish BioFINDER study | 0.7 | 6 | Citations (PDF) |
| 119 | Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease | 0.7 | 33 | Citations (PDF) |
| 120 | A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis | 5.4 | 53 | Citations (PDF) |
| 121 | Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures | 25.6 | 291 | Citations (PDF) |
| 122 | Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau | 7.2 | 102 | Citations (PDF) |
| 123 | Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjectsBrain, 2021, 144, 2826-2836 | 8.9 | 80 | Citations (PDF) |
| 124 | Biomarkers for neurodegenerative diseases | 25.6 | 592 | Citations (PDF) |
| 125 | Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations | 14.1 | 145 | Citations (PDF) |
| 126 | A multicentre validation study of the diagnostic value of plasma neurofilament light | 14.1 | 284 | Citations (PDF) |
| 127 | Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson's disease | 1.9 | 12 | Citations (PDF) |
| 128 | Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers | 7.2 | 75 | Citations (PDF) |
| 129 | Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s diseaseBrain, 2021, 144, 3505-3516 | 8.9 | 277 | Citations (PDF) |
| 130 | Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience | 3.8 | 1 | Citations (PDF) |
| 131 | Tau-related grey matter network breakdown across the Alzheimer’s disease continuum | 6.7 | 13 | Citations (PDF) |
| 132 | Management of Alzheimer's disease takes a leap forward | 19.1 | 4 | Citations (PDF) |
| 133 | Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease | 14.3 | 183 | Citations (PDF) |
| 134 | Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays | 1.3 | 79 | Citations (PDF) |
| 135 | Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease | 14.3 | 263 | Citations (PDF) |
| 136 | Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study | 19.1 | 280 | Citations (PDF) |
| 137 | Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts | 5.4 | 13 | Citations (PDF) |
| 138 | The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease | 0.7 | 217 | Citations (PDF) |
| 139 | Sex differences in off-target binding using tau positron emission tomography | 3.5 | 24 | Citations (PDF) |
| 140 | The global Alzheimer's Association round robin study on plasma amyloid β methods | 2.6 | 20 | Citations (PDF) |
| 141 | Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer’s Disease | 1.5 | 4 | Citations (PDF) |
| 142 | Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease | 3.7 | 8 | Citations (PDF) |
| 143 | Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers | 0.7 | 7 | Citations (PDF) |
| 144 | Ability of tau‐PET, phospho‐tau217, NfL and cortical thickness to predict short‐term cognitive decline in early symptomatic Alzheimer’s disease | 0.7 | 0 | Citations (PDF) |
| 145 | Unravelling drivers of age‐ and beta‐amyloid‐related neurodegeneration in medial temporal lobe atrophy in cognitively normal older adults | 0.7 | 0 | Citations (PDF) |
| 146 | Establishment of updated biomarker cut‐off values for the second‐generation Elecsys β‐amyloid(1–42), pTau and tTau CSF immunoassays | 0.7 | 0 | Citations (PDF) |
| 147 | Soluble P‐tau217 reflects both amyloid and tau pathology in the human brain and mediates the association of amyloid with neocortical tau | 0.7 | 0 | Citations (PDF) |
| 148 | Inflammatory, degeneration and neuritic growth biomarkers predict cognitive decline and dementia in Parkinson’s disease | 0.7 | 0 | Citations (PDF) |
| 149 | Biomarker driven enrichment strategies for tau pathology in AD clinical trials | 0.7 | 0 | Citations (PDF) |
| 150 | Impact of reduced injected dose on the quantification of [
<sup>18</sup>
F]RO948 and [
<sup>18</sup>
F]Flortaucipir PET for
<i>in vivo</i>
tau pathology | 0.7 | 1 | Citations (PDF) |
| 151 | Tau and synaptic biomarkers but not amyloid‐β are associated with cerebral perfusion in the Alzheimer’s disease spectrum | 0.7 | 0 | Citations (PDF) |
| 152 | Plasma glial fibrillary acidic protein is an early and specific marker of amyloid‐β pathology in Alzheimer’s disease | 0.7 | 1 | Citations (PDF) |
| 153 | Tau deposition is associated with grey matter network breakdown across different stages of the Alzheimer’s disease continuum | 0.7 | 0 | Citations (PDF) |
| 154 | Plasma biomarkers predict longitudinal amyloid accumulation, tau burden, brain atrophy and cognitive decline in early Alzheimer’s disease | 0.7 | 0 | Citations (PDF) |
| 155 | Lower cognitive resilience against brain atrophy in cognitively unimpaired elderly is partly explained by Alzheimer's disease pathology | 0.7 | 0 | Citations (PDF) |
| 156 | Towards a universal cortical tau sampling mask | 0.7 | 2 | Citations (PDF) |
| 157 | Comparing the clinical utility and diagnostic performance of cerebrospinal fluid P‐tau181, P‐tau217 and P‐tau231 assays | 0.7 | 0 | Citations (PDF) |
| 158 | Amyloid‐β accumulation is independently related to executive function in cognitively unimpaired adults | 0.7 | 0 | Citations (PDF) |
| 159 | Associations between cerebrospinal fluid markers of neuroinflammation and longitudinal measurements of white matter lesions | 0.7 | 0 | Citations (PDF) |
| 160 | Associations between longitudinal neuropsychiatric symptoms and biomarkers of beta‐amyloid, tau, neurodegeneration, and cognitive decline | 0.7 | 1 | Citations (PDF) |
| 161 | The association between diet in mid‐life and dementia incidence over a 20‐year period | 0.7 | 0 | Citations (PDF) |
| 162 | Potential drivers of age‐ and beta‐amyloid‐related neurodegeneration in early and late Alzheimer’s Disease regions in cognitively normal older adults | 0.7 | 0 | Citations (PDF) |
| 163 | Prediction of future Alzheimer’s disease dementia using plasma phospho‐tau combined with other accessible measures | 0.7 | 3 | Citations (PDF) |
| 164 | [
<sup>18</sup>
F]RO948 tau PET in bvFTD due to
<i>C9orf72</i>
and
<i>GRN</i>
mutations | 0.7 | 0 | Citations (PDF) |
| 165 | Apathy and anxiety are early markers of Alzheimer's disease | 3.4 | 122 | Citations (PDF) |
| 166 | Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration | 5.2 | 17 | Citations (PDF) |
| 167 | Distinct tau PET patterns in atrophy‐defined subtypes of Alzheimer's disease | 0.7 | 78 | Citations (PDF) |
| 168 | Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia | 6.6 | 55 | Citations (PDF) |
| 169 | Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease | 2.1 | 61 | Citations (PDF) |
| 170 | Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathologyBrain, 2020, 143, 650-660 | 8.9 | 78 | Citations (PDF) |
| 171 | Cerebrospinal Fluid Levels of Neurogranin in Parkinsonian Disorders | 5.3 | 26 | Citations (PDF) |
| 172 | Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s diseaseBrain, 2020, 143, 3234-3241 | 8.9 | 176 | Citations (PDF) |
| 173 | Validation 2020, , 277-308 | | 1 | Citations (PDF) |
| 174 | Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies | 6.4 | 141 | Citations (PDF) |
| 175 | Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias | 19.1 | 330 | Citations (PDF) |
| 176 | Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load | 1.3 | 12 | Citations (PDF) |
| 177 | Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer’s dementia | 6.7 | 8 | Citations (PDF) |
| 178 | Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer’s disease | 11.3 | 97 | Citations (PDF) |
| 179 | LifeTime and improving European healthcare through cell-based interceptive medicine | 40.1 | 110 | Citations (PDF) |
| 180 | Allele drop-out and the stochastic threshold 2020, , 89-110 | | 0 | Citations (PDF) |
| 181 | Low-template DNA 2020, , 111-128 | | 0 | Citations (PDF) |
| 182 | A qualitative (semi-continuous) model: LRmix Studio 2020, , 153-179 | | 0 | Citations (PDF) |
| 183 | Investigative forensic genetics: SmartRank, CaseSolver and DNAmatch2 2020, , 339-383 | | 0 | Citations (PDF) |
| 184 | Forensic genetics: the basics 2020, , 1-53 | | 3 | Citations (PDF) |
| 185 | Empirical characterization of DNA profiles 2020, , 55-88 | | 1 | Citations (PDF) |
| 186 | Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders | 13.7 | 768 | Citations (PDF) |
| 187 | Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease | 3.4 | 44 | Citations (PDF) |
| 188 | Comparing progression biomarkers in clinical trials of early Alzheimer’s disease | 3.8 | 27 | Citations (PDF) |
| 189 | Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases | 3.5 | 17 | Citations (PDF) |
| 190 | Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotypePain, 2020, 161, 2142-2154 | 4.6 | 12 | Citations (PDF) |
| 191 | Plasma <scp>NT1</scp> Tau is a Specific and Early Marker of Alzheimer's Disease | 6.6 | 25 | Citations (PDF) |
| 192 | Modeling patient‐specific tau spreading patterns in Alzheimer’s disease: Towards precision medicine | 0.7 | 3 | Citations (PDF) |
| 193 | The accumulation rate of tau aggregates is higher in females and younger individuals | 0.7 | 2 | Citations (PDF) |
| 194 | Improved performance of Elecsys CSF Abeta measurement achieved using the simple, unified routine‐use protocol for CSF collection | 0.7 | 0 | Citations (PDF) |
| 195 | Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies | 14.1 | 38 | Citations (PDF) |
| 196 | High circulating levels of midregional proenkephalin A predict vascular dementia: a population-based prospective study | 3.7 | 8 | Citations (PDF) |
| 197 | CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers | 3.7 | 16 | Citations (PDF) |
| 198 | Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders | 14.3 | 141 | Citations (PDF) |
| 199 | The implications of different approaches to define AT(N) in Alzheimer disease | 1.3 | 86 | Citations (PDF) |
| 200 | Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease | 14.1 | 303 | Citations (PDF) |
| 201 | Maximizing Safety in the Conduct of Alzheimer’s Disease Fluid Biomarker Research in the Era of COVID-19 | 2.7 | 7 | Citations (PDF) |
| 202 | Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up | 3.5 | 12 | Citations (PDF) |
| 203 | Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease | 5.2 | 65 | Citations (PDF) |
| 204 | The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment | 6.7 | 16 | Citations (PDF) |
| 205 | Medial temporal lobe connectivity and its associations with cognition in early Alzheimer’s diseaseBrain, 2020, 143, 1233-1248 | 8.9 | 170 | Citations (PDF) |
| 206 | Towards unconstrained compartment modeling in white matter using diffusion‐relaxation MRI with tensor‐valued diffusion encoding | 3.1 | 66 | Citations (PDF) |
| 207 | Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease | 14.3 | 88 | Citations (PDF) |
| 208 | Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia | 25.6 | 709 | Citations (PDF) |
| 209 | Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases | 6.7 | 30 | Citations (PDF) |
| 210 | [18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case | 7.9 | 6 | Citations (PDF) |
| 211 | Beta-blocker therapy and risk of vascular dementia: A population-based prospective study | 2.1 | 24 | Citations (PDF) |
| 212 | Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease | 14.1 | 194 | Citations (PDF) |
| 213 | Alcohol Consumption and Risk of Parkinson's Disease: Data From a Large Prospective European Cohort | 5.3 | 25 | Citations (PDF) |
| 214 | Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease | 14.1 | 283 | Citations (PDF) |
| 215 | Relationship between cortical iron and tau aggregation in Alzheimer’s diseaseBrain, 2020, 143, 1341-1349 | 8.9 | 122 | Citations (PDF) |
| 216 | Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease | 11.3 | 220 | Citations (PDF) |
| 217 | Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts | 19.1 | 737 | Citations (PDF) |
| 218 | The A4 study: <i>β</i>‐amyloid and cognition in 4432 cognitively unimpaired adults | 3.8 | 53 | Citations (PDF) |
| 219 | Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults | 3.4 | 15 | Citations (PDF) |
| 220 | Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations | 8.5 | 112 | Citations (PDF) |
| 221 | The impact of demographic, clinical, genetic, and imaging variables on tau PET status | 5.4 | 28 | Citations (PDF) |
| 222 | Reporting frequency of radiology findings increases after introducing visual rating scales in the primary care diagnostic work up of subjective and mild cognitive impairment | 3.8 | 5 | Citations (PDF) |
| 223 | Pre‐analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF | 2.6 | 23 | Citations (PDF) |
| 224 | Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia | 14.1 | 72 | Citations (PDF) |
| 225 | The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjectsBrain, 2020, 143, 3805-3815 | 8.9 | 71 | Citations (PDF) |
| 226 | Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias | 1.3 | 37 | Citations (PDF) |
| 227 | Regional times to equilibria and their impact on semi-quantification of [<sup>18</sup>F]AV-1451 uptake | 4.9 | 5 | Citations (PDF) |
| 228 | β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly | 3.7 | 27 | Citations (PDF) |
| 229 | European Ultrahigh‐Field Imaging Network for Neurodegenerative Diseases (EUFIND) | 2.6 | 16 | Citations (PDF) |
| 230 | Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study | 2.4 | 10 | Citations (PDF) |
| 231 | Determining clinically meaningful decline in preclinical Alzheimer disease | 1.3 | 94 | Citations (PDF) |
| 232 | Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease | 2.1 | 10 | Citations (PDF) |
| 233 | Staging <b>β</b>-Amyloid Pathology With Amyloid Positron Emission Tomography | 14.3 | 164 | Citations (PDF) |
| 234 | Towards a unified protocol for handling of CSF before β-amyloid measurements | 6.7 | 43 | Citations (PDF) |
| 235 | Primary fatty amides are potential plasma biomarkers for AD | 9.2 | 0 | Citations (PDF) |
| 236 | α-synuclein−lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients | 7.7 | 37 | Citations (PDF) |
| 237 | Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α-Synucleinopathies | 9.6 | 24 | Citations (PDF) |
| 238 | Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid | 4.5 | 48 | Citations (PDF) |
| 239 | Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease | 7.2 | 234 | Citations (PDF) |
| 240 | Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease | 5.1 | 163 | Citations (PDF) |
| 241 | A quick test of cognitive speed can predict development of dementia in Parkinson’s disease | 3.7 | 12 | Citations (PDF) |
| 242 | Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimer’s disease | 6.7 | 31 | Citations (PDF) |
| 243 | Increased functional connectivity of thalamic subdivisions in patients with Parkinson’s disease | 2.5 | 14 | Citations (PDF) |
| 244 | Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study | 19.1 | 89 | Citations (PDF) |
| 245 | Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease | 6.7 | 55 | Citations (PDF) |
| 246 | Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline | 2.3 | 4 | Citations (PDF) |
| 247 | Predicting diagnosis and cognition with<sup>18</sup>F‐AV‐1451 tau PET and structural MRI in Alzheimer's disease | 0.7 | 71 | Citations (PDF) |
| 248 | Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid | 1.8 | 70 | Citations (PDF) |
| 249 | Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS | 1.8 | 33 | Citations (PDF) |
| 250 | Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology | 14.3 | 529 | Citations (PDF) |
| 251 | Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease | 2.5 | 19 | Citations (PDF) |
| 252 | A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies | 0.7 | 19 | Citations (PDF) |
| 253 | Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status | 14.3 | 312 | Citations (PDF) |
| 254 | <scp>CSF</scp> placental growth factor – a novel candidate biomarker of frontotemporal dementia | 3.8 | 11 | Citations (PDF) |
| 255 | Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia | 2.0 | 19 | Citations (PDF) |
| 256 | Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer’s Disease | 2.7 | 13 | Citations (PDF) |
| 257 | Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression | 7.4 | 47 | Citations (PDF) |
| 258 | Application of advanced brain positron emission tomography–based molecular imaging for a biological framework in neurodegenerative proteinopathies | 2.6 | 6 | Citations (PDF) |
| 259 | Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease | 6.7 | 356 | Citations (PDF) |
| 260 | 18F-Flortaucipir in TDP-43 associated frontotemporal dementia | 3.7 | 28 | Citations (PDF) |
| 261 | Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism | 3.7 | 25 | Citations (PDF) |
| 262 | Extreme sleep pattern in Lewy body dementia: a hypothalamic matter? | 0.4 | 4 | Citations (PDF) |
| 263 | Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly | 2.9 | 41 | Citations (PDF) |
| 264 | Searching for the neurite density with diffusion MRI: Challenges for biophysical modeling | 3.8 | 92 | Citations (PDF) |
| 265 | CSF and blood biomarkers for Parkinson's disease | 19.1 | 446 | Citations (PDF) |
| 266 | Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein | 3.7 | 7 | Citations (PDF) |
| 267 | P1588Beta-blocker therapy and risk of dementia: a population-based prospective study | 2.2 | 0 | Citations (PDF) |
| 268 | DT‐01‐04: DIAGNOSTIC PERFORMANCE OF [<sup>18</sup>F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDER‐2 STUDY | 0.7 | 0 | Citations (PDF) |
| 269 | P.780 Apathy and anxiety are early markers of Alzheimer's disease | 0.9 | 0 | Citations (PDF) |
| 270 | Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume | 6.7 | 15 | Citations (PDF) |
| 271 | Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays | 3.7 | 137 | Citations (PDF) |
| 272 | Brain myoinositol as a potential marker of amyloid-related pathology | 1.3 | 35 | Citations (PDF) |
| 273 | Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease | 1.3 | 212 | Citations (PDF) |
| 274 | Data‐driven approaches for tau‐PET imaging biomarkers in Alzheimer's disease | 3.8 | 30 | Citations (PDF) |
| 275 | Accurate risk estimation of β‐amyloid positivity to identify prodromal Alzheimer's disease: Cross‐validation study of practical algorithms | 0.7 | 52 | Citations (PDF) |
| 276 | Correlation of In Vivo [<sup>18</sup>F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology | 14.3 | 80 | Citations (PDF) |
| 277 | Parkinson’s disease: evolution of cognitive impairment and CSF Aβ<sub>1–42</sub> profiles in a prospective longitudinal study | 2.0 | 17 | Citations (PDF) |
| 278 | Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948 | 5.4 | 61 | Citations (PDF) |
| 279 | A Deep Learning Approach to MR-less Spatial Normalization for Tau PET Images | 0.0 | 2 | Citations (PDF) |
| 280 | CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts | 0.7 | 510 | Citations (PDF) |
| 281 | Amyloid blood biomarker detects Alzheimer's disease | 7.2 | 152 | Citations (PDF) |
| 282 | Alteration of putaminal fractional anisotropy in Parkinson’s disease: a longitudinal diffusion kurtosis imaging study | 2.3 | 21 | Citations (PDF) |
| 283 | Amyloid pathology in the progression to mild cognitive impairment | 3.4 | 20 | Citations (PDF) |
| 284 | Comparing
<sup>18</sup>
F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease | 1.3 | 83 | Citations (PDF) |
| 285 | Altered structural network organization in cognitively normal individuals with amyloid pathology | 3.4 | 29 | Citations (PDF) |
| 286 | Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review | 6.7 | 29 | Citations (PDF) |
| 287 | Is longitudinal tau PET ready for use in Alzheimer’s disease clinical trials?Brain, 2018, 141, 1241-1244 | 8.9 | 7 | Citations (PDF) |
| 288 | Amyloid Network Topology Characterizes the Progression of Alzheimer’s Disease During the Predementia Stages | 2.9 | 28 | Citations (PDF) |
| 289 | Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease | 0.7 | 63 | Citations (PDF) |
| 290 | 18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies | 3.7 | 65 | Citations (PDF) |
| 291 | Striatal changes in Parkinson disease: An investigation of morphology, functional connectivity and their relationship to clinical symptoms | 1.9 | 37 | Citations (PDF) |
| 292 | Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle‐aged or elderly people | 0.7 | 21 | Citations (PDF) |
| 293 | Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer’s Disease | 2.9 | 33 | Citations (PDF) |
| 294 | Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia | 14.1 | 121 | Citations (PDF) |
| 295 | Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later | 1.3 | 78 | Citations (PDF) |
| 296 | P3‐413: HETEROGENEOUS TAU‐PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY | 0.7 | 0 | Citations (PDF) |
| 297 | P3‐267: ANALYSIS OF CEREBROSPINAL FLUID (CSF) BIOMARKERS TO PREDICT RISK OF CLINICAL DECLINE AND PROGRESSION TO DEMENTIA IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD COGNITIVE SYMPTOMS | 0.7 | 1 | Citations (PDF) |
| 298 | IC‐P‐224: HETEROGENEOUS TAU‐PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY | 0.7 | 0 | Citations (PDF) |
| 299 | Exploring causality of the association between smoking and Parkinson’s disease | 5.2 | 63 | Citations (PDF) |
| 300 | O2‐09‐02: A UNIFIED PRE‐ANALYTICAL PROTOCOL FOR HANDLING OF CSF SAMPLES BEFORE ANALYSES OF AD BIOMARKER LEVELS | 0.7 | 0 | Citations (PDF) |
| 301 | IC‐P‐036: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NON‐DEMENTED ELDERLY SUBJECTS | 0.7 | 0 | Citations (PDF) |
| 302 | Genetic characterization of amyloid-β and tau network spread | 25.6 | 1 | Citations (PDF) |
| 303 | Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia | 6.6 | 144 | Citations (PDF) |
| 304 | Dietary intervention with an Okinawan-based Nordic diet in type 2 diabetes renders decreased interleukin-18 concentrations and increased neurofilament light concentrations in plasma | 2.9 | 13 | Citations (PDF) |
| 305 | Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders | 3.7 | 111 | Citations (PDF) |
| 306 | Discriminative Accuracy of [<sup>18</sup>F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders | 13.7 | 312 | Citations (PDF) |
| 307 | The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review | 0.7 | 91 | Citations (PDF) |
| 308 | CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease | 1.3 | 236 | Citations (PDF) |
| 309 | Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease | 3.4 | 15 | Citations (PDF) |
| 310 | Molecular properties underlying regional vulnerability to Alzheimer’s disease pathology | 8.9 | 78 | Citations (PDF) |
| 311 | Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease | 6.7 | 21 | Citations (PDF) |
| 312 | Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study | 6.7 | 56 | Citations (PDF) |
| 313 | The clinical significance of 10-m walk test standardizations in Parkinson’s disease | 3.4 | 41 | Citations (PDF) |
| 314 | Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease | 7.9 | 125 | Citations (PDF) |
| 315 | Genome editing (CRISPR-Cas9) to identify and characterise functional variants determining metformin response 2018, , | | 0 | Citations (PDF) |
| 316 | Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium | 2.7 | 38 | Citations (PDF) |
| 317 | The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals | 2.6 | 20 | Citations (PDF) |
| 318 | Blood-based NfL | 1.3 | 384 | Citations (PDF) |
| 319 | Characterisation of artefacts and drop-in events using STR-validator and single-cell analysis | 2.4 | 24 | Citations (PDF) |
| 320 | <scp>I</scp>ncreased basal ganglia binding of <sup>18</sup><scp>F‐AV‐1451</scp> in patients with progressive supranuclear palsy | 5.3 | 109 | Citations (PDF) |
| 321 | Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease | 3.4 | 95 | Citations (PDF) |
| 322 | Tau oligomers in cerebrospinal fluid in Alzheimer's disease | 3.8 | 61 | Citations (PDF) |
| 323 | Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorderBrain, 2017, 140, e33-e33 | 8.9 | 2 | Citations (PDF) |
| 324 | Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework | 3.4 | 104 | Citations (PDF) |
| 325 | Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer’s disease | 7.7 | 177 | Citations (PDF) |
| 326 | Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype | 3.4 | 173 | Citations (PDF) |
| 327 | Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders | 2.3 | 22 | Citations (PDF) |
| 328 | Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity | 14.1 | 587 | Citations (PDF) |
| 329 | A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease | 3.7 | 43 | Citations (PDF) |
| 330 | [IC‐02–05]: ABNORMAL STRUCTURAL BRAIN CONNECTOME IN INDIVIDUALS WITH PRECLINICAL ALZHEIMER's DISEASE | 0.7 | 1 | Citations (PDF) |
| 331 | CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients | 3.4 | 87 | Citations (PDF) |
| 332 | No independent association between pulse wave velocity and dementia | 1.2 | 18 | Citations (PDF) |
| 333 | In vivo retention of
<sup>18</sup>
F-AV-1451 in corticobasal syndrome | 1.3 | 104 | Citations (PDF) |
| 334 | <sup>18</sup>F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease | 7.2 | 149 | Citations (PDF) |
| 335 | Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson’s disease: protocol for a systematic review and individual participant data meta-analysis | 2.0 | 4 | Citations (PDF) |
| 336 | Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers | 19.1 | 483 | Citations (PDF) |
| 337 | MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia? | 2.8 | 54 | Citations (PDF) |
| 338 | Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40) | 6.7 | 17 | Citations (PDF) |
| 339 | Psychometric testing of a Swedish version of the Apathy Evaluation Scale | 1.8 | 5 | Citations (PDF) |
| 340 | Heterozygous PINK1 p.G411S increases risk of Parkinson’s disease via a dominant-negative mechanism | 8.9 | 114 | Citations (PDF) |
| 341 | Modeling Strategies for Quantification of In Vivo <sup>18</sup>F-AV-1451 Binding in Patients with Tau Pathology | 6.6 | 53 | Citations (PDF) |
| 342 | Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment | 14.3 | 101 | Citations (PDF) |
| 343 | [IC‐P‐123]: ATROPHY OF THE POSTERIOR SUBICULUM IS ASSOCIATED WITH MEMORY IMPAIRMENT, TAU AND Aβ PATHOLOGY IN NON‐DEMENTED INDIVIDUALS | 0.7 | 0 | Citations (PDF) |
| 344 | [P3–132]: CSF BIOMARKERS OF NEUROINFLAMMATION ARE ELEVATED IN PRECLINICAL AND PRODROMAL AD AND CORRELATE WITH TAU PATHOLOGY | 0.7 | 0 | Citations (PDF) |
| 345 | [P3–402]: PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE AND AMYLOID PATHOLOGY EXHIBIT SIGNIFICANT BRAIN ATROPHY, TAU PATHOLOGY AND MILD MEMORY DIFFICULTIES | 0.7 | 0 | Citations (PDF) |
| 346 | [P4–152]: DIFFERENCES IN ANALYTICAL SELECTIVITY OF β‐AMYLOID (1–42) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS | 0.7 | 1 | Citations (PDF) |
| 347 | [P4–197]: EMERGING AMYLOID PATHOLOGY | 0.7 | 0 | Citations (PDF) |
| 348 | [P1–150]: INVESTIGATION OF THE ASSOCIATION BETWEEN GENETIC VARIATION IN <i>IL1RAP</i> AND ALZHEIMER's‐RELATED CSF‐BIOMARKERS | 0.7 | 0 | Citations (PDF) |
| 349 | [IC‐P‐098]: ASSOCIATION BETWEEN CEREBROSPINAL FLUID AND PLASMA NEURODEGENERATION BIOMARKERS WITH BRAIN ATROPHY IN ALZHEIMER's DISEASE | 0.7 | 0 | Citations (PDF) |
| 350 | [IC‐P‐199]: [18]F‐AV‐1451 PET IN CLINICALLY DIAGNOSED CORTICOBASAL DEGENERATION | 0.7 | 0 | Citations (PDF) |
| 351 | [P2–246]: NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER's DISEASE AND TAUOPATHIES | 0.7 | 0 | Citations (PDF) |
| 352 | Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s diseaseBrain, 2017, 140, 2286-2294 | 8.9 | 140 | Citations (PDF) |
| 353 | 1947Biomarkers of microvascular endothelial dysfunction may predict dementia | 2.2 | 0 | Citations (PDF) |
| 354 | P4237N-terminal prosomatostatin predicts vascular dementia but not alzheimers disease | 2.2 | 0 | Citations (PDF) |
| 355 | Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and Aβ Pathology in Non-demented Individuals | 4.1 | 29 | Citations (PDF) |
| 356 | Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks | 3.0 | 74 | Citations (PDF) |
| 357 | Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease | 3.0 | 61 | Citations (PDF) |
| 358 | The effect of white matter hyperintensities on statistical analysis of diffusion tensor imaging in cognitively healthy elderly and prodromal Alzheimer's disease | 2.5 | 33 | Citations (PDF) |
| 359 | Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations | 6.7 | 22 | Citations (PDF) |
| 360 | A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease | 2.7 | 28 | Citations (PDF) |
| 361 | Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes | 2.7 | 63 | Citations (PDF) |
| 362 | <sup>18</sup>F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in<i>MAPT</i>mutation carriersBrain, 2016, 139, 2372-2379 | 8.9 | 148 | Citations (PDF) |
| 363 | Reply: Do we still need positron emission tomography for early Alzheimer’s disease diagnosis?Brain, 2016, 139, e61-e61 | 8.9 | 4 | Citations (PDF) |
| 364 | Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET | 3.7 | 55 | Citations (PDF) |
| 365 | Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer’s Disease Patient with Presenilin-1 Mutation | 2.7 | 28 | Citations (PDF) |
| 366 | P4‐339: Early‐ and Late‐Onset Alzheimer’S Disease are Associated with Distinct Regional TAU Pathology as Examined with [18]F‐AV‐1451 TAU Positron Emission Tomography | 0.7 | 0 | Citations (PDF) |
| 367 | Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism | 3.7 | 6 | Citations (PDF) |
| 368 | The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease | 6.7 | 141 | Citations (PDF) |
| 369 | Maturity of Aβ42, tau, and phospho-tau in the cerebrospinal fluid as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework | 3.4 | 1 | Citations (PDF) |
| 370 | Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomographyBrain, 2016, 139, 1226-1236 | 8.9 | 302 | Citations (PDF) |
| 371 | Myo-inositol changes precede amyloid pathology and relate to
<i>APOE</i>
genotype in Alzheimer disease | 1.3 | 70 | Citations (PDF) |
| 372 | Clinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient? | 19.1 | 10 | Citations (PDF) |
| 373 | Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment | 3.4 | 28 | Citations (PDF) |
| 374 | External validation of a 3-step falls prediction model in mild Parkinson’s disease | 3.4 | 25 | Citations (PDF) |
| 375 | Plasma tau in Alzheimer disease | 1.3 | 392 | Citations (PDF) |
| 376 | Cerebrospinal fluid neurogranin and
<scp>YKL</scp>
‐40 as biomarkers of Alzheimer's disease | 3.8 | 147 | Citations (PDF) |
| 377 | <scp>L</scp>ongitudinal <scp>M</scp>easurements of <scp>C</scp>erebrospinal <scp>F</scp>luid <scp>B</scp>iomarkers in <scp>P</scp>arkinson's <scp>D</scp>isease | 5.3 | 140 | Citations (PDF) |
| 378 | Assessing risk for preclinical β‐amyloid pathology with <i>APOE</i>, cognitive, and demographic information | 2.6 | 49 | Citations (PDF) |
| 379 | Reference measurement procedure for <scp>CSF</scp> amyloid beta (Aβ)<sub>1–42</sub> and the <scp>CSF</scp> Aβ<sub>1–42</sub>/Aβ<sub>1–40</sub> ratio – a cross‐validation study against amyloid <scp>PET</scp> | 4.0 | 77 | Citations (PDF) |
| 380 | The Swedish SCOPA-SLEEP for assessment of sleep disorders in Parkinson’s disease and healthy controls | 2.2 | 8 | Citations (PDF) |
| 381 | Plasma β-amyloid in Alzheimer’s disease and vascular disease | 3.7 | 464 | Citations (PDF) |
| 382 | Brain activity and Alzheimer’s disease: a complex relationshipBrain, 2016, 139, 2109-2110 | 8.9 | 2 | Citations (PDF) |
| 383 | Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis | 14.1 | 47 | Citations (PDF) |
| 384 | Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease | 6.7 | 114 | Citations (PDF) |
| 385 | <scp>CSF</scp> A<i>β</i>42/A<i>β</i>40 and A<i>β</i>42/A<i>β</i>38 ratios: better diagnostic markers of Alzheimer disease | 3.8 | 343 | Citations (PDF) |
| 386 | Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy | 7.9 | 59 | Citations (PDF) |
| 387 | Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process | 2.0 | 25 | Citations (PDF) |
| 388 | Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson’s Disease | 2.5 | 36 | Citations (PDF) |
| 389 | Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer’s disease and other neurodegenerative diseases | 1.0 | 36 | Citations (PDF) |
| 390 | Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9‐year study | 2.6 | 23 | Citations (PDF) |
| 391 | Hepatocyte growth factor in cerebrospinal fluid differentiates community-acquired or nosocomial septic meningitis from other causes of pleocytosis | 5.6 | 6 | Citations (PDF) |
| 392 | Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients | 6.7 | 24 | Citations (PDF) |
| 393 | Prediction of Falls and/or Near Falls in People with Mild Parkinson’s Disease | 2.5 | 64 | Citations (PDF) |
| 394 | Spatial navigation measured by the Floor Maze Test in patients with subjective cognitive impairment, mild cognitive impairment, and mild Alzheimer's disease | 1.0 | 29 | Citations (PDF) |
| 395 | CSF biomarkers and clinical progression of Parkinson disease | 1.3 | 181 | Citations (PDF) |
| 396 | An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics—Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease | 3.7 | 75 | Citations (PDF) |
| 397 | Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease | 0.7 | 263 | Citations (PDF) |
| 398 | Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjectsBrain, 2015, 138, 2701-2715 | 8.9 | 109 | Citations (PDF) |
| 399 | Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease | 2.1 | 1 | Citations (PDF) |
| 400 | Plasma amyloid‐β and risk of Alzheimer's disease in the Framingham Heart Study | 0.7 | 98 | Citations (PDF) |
| 401 | Genotyping and interpretation of STR-DNA: Low-template, mixtures and database matches—Twenty years of research and development | 2.4 | 130 | Citations (PDF) |
| 402 | Amyloid biomarkers in Alzheimer's disease | 14.8 | 387 | Citations (PDF) |
| 403 | Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy | 2.3 | 34 | Citations (PDF) |
| 404 | Increased CSF biomarkers of angiogenesis in Parkinson disease | 1.3 | 119 | Citations (PDF) |
| 405 | Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls | 6.7 | 107 | Citations (PDF) |
| 406 | Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease | 1.3 | 281 | Citations (PDF) |
| 407 | The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies | 2.5 | 90 | Citations (PDF) |
| 408 | Extrapolation-Based References Improve Motion and Eddy-Current Correction of High B-Value DWI Data: Application in Parkinson’s Disease Dementia | 2.5 | 74 | Citations (PDF) |
| 409 | Increased Levels of Hyaluronic Acid in Cerebrospinal Fluid in Patients with Vascular Dementia | 2.7 | 33 | Citations (PDF) |
| 410 | SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease | 14.2 | 218 | Citations (PDF) |
| 411 | Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42 | 14.3 | 306 | Citations (PDF) |
| 412 | Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease | 14.1 | 86 | Citations (PDF) |
| 413 | A porous silicon immunoassay platform for fluorometric determination of α-synuclein in human cerebrospinal fluid | 4.8 | 8 | Citations (PDF) |
| 414 | Factors associated with fear of falling in people with Parkinson’s disease | 2.1 | 76 | Citations (PDF) |
| 415 | Low Levels of Soluble NG2 in Cerebrospinal Fluid from Patients with Dementia with Lewy Bodies | 2.7 | 16 | Citations (PDF) |
| 416 | Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls | 7.9 | 128 | Citations (PDF) |
| 417 | Assessment of Peptide Chemical Modifications on the Development of an Accurate and Precise Multiplex Selected Reaction Monitoring Assay for Apolipoprotein E Isoforms | 3.7 | 48 | Citations (PDF) |
| 418 | Flt3 ligand does not differentiate between Parkinsonian disorders | 5.3 | 9 | Citations (PDF) |
| 419 | STR-validator: An open source platform for validation and process control | 2.4 | 17 | Citations (PDF) |
| 420 | Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study | 2.1 | 47 | Citations (PDF) |
| 421 | The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean? | 0.7 | 249 | Citations (PDF) |
| 422 | Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease | 6.7 | 171 | Citations (PDF) |
| 423 | CSF biomarkers for Alzheimer’s pathology and the effect size of APOE ɛ4 | 8.3 | 28 | Citations (PDF) |
| 424 | P4-023: INCREASED LEVELS OF ANGIOGENIC FACTORS IN THE CEREBROSPINAL FLUID ARE ASSOCIATED WITH COGNITIVE IMPAIRMENT IN PARKINSOŃS DISEASE 2014, 10, P791-P791 | | 0 | Citations (PDF) |
| 425 | P2-101: EVALUATION OF THE PRESYNAPTIC PROTEIN SNAP-25 AS A NOVEL CEREBROSPINAL FLUID MARKER FOR SYNAPTIC PATHOLOGY IN ALZHEIMER'S DISEASE 2014, 10, P508-P508 | | 0 | Citations (PDF) |
| 426 | β-amyloid Peptides and Amyloid Plaques in Alzheimer's Disease | 6.5 | 226 | Citations (PDF) |
| 427 | Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia | 2.7 | 105 | Citations (PDF) |
| 428 | Fluid biomarkers in Alzheimer’s disease – current concepts | 14.2 | 174 | Citations (PDF) |
| 429 | Plasma tau levels in Alzheimer's disease | 6.7 | 330 | Citations (PDF) |
| 430 | NG2 cells, a new trail for Alzheimer’s disease mechanisms? | 5.1 | 47 | Citations (PDF) |
| 431 | Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease | 2.5 | 39 | Citations (PDF) |
| 432 | Free open source software for internal validation of forensic STR typing kits | 0.5 | 1 | Citations (PDF) |
| 433 | Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease | 2.5 | 64 | Citations (PDF) |
| 434 | Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease | 2.5 | 36 | Citations (PDF) |
| 435 | Cerebrospinal fluid inflammatory markers in Parkinson’s disease – Associations with depression, fatigue, and cognitive impairment | 4.3 | 216 | Citations (PDF) |
| 436 | Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters | 2.5 | 52 | Citations (PDF) |
| 437 | A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of Aβ38, Aβ40, and Aβ42 in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls | 2.7 | 91 | Citations (PDF) |
| 438 | Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies | 2.4 | 24 | Citations (PDF) |
| 439 | Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis | 1.3 | 129 | Citations (PDF) |
| 440 | Diagnostic Power of 24S-Hydroxycholesterol in Cerebrospinal Fluid: Candidate Marker of Brain Health | 2.7 | 32 | Citations (PDF) |
| 441 | Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia | 2.7 | 39 | Citations (PDF) |
| 442 | Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy | 2.5 | 127 | Citations (PDF) |
| 443 | Proinflammatory Cytokines Are Elevated in Serum of Patients with Multiple System Atrophy | 2.5 | 40 | Citations (PDF) |
| 444 | Assessment of Global and Regional Diffusion Changes along White Matter Tracts in Parkinsonian Disorders by MR Tractography | 2.5 | 27 | Citations (PDF) |
| 445 | Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease | 2.5 | 42 | Citations (PDF) |
| 446 | Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease | 2.5 | 121 | Citations (PDF) |
| 447 | Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia | 14.4 | 545 | Citations (PDF) |
| 448 | Age and diagnostic performance of Alzheimer disease CSF biomarkers | 1.3 | 143 | Citations (PDF) |
| 449 | Evaluation of Plasma Aβ as Predictor of Alzheimer's Disease in Older Individuals Without Dementia: A Population-Based Study | 2.7 | 43 | Citations (PDF) |
| 450 | Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease | 3.4 | 52 | Citations (PDF) |
| 451 | First-Degree Relatives of Type 2 Diabetic Patients Have Reduced Expression of Genes Involved in Fatty Acid Metabolism in Skeletal Muscle | 4.4 | 21 | Citations (PDF) |
| 452 | Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders | 6.8 | 404 | Citations (PDF) |
| 453 | Identification of SPARC-like 1 Protein as Part of a Biomarker Panel for Alzheimer's Disease in Cerebrospinal Fluid | 2.7 | 49 | Citations (PDF) |
| 454 | Amyloid-β Oligomers in Cerebrospinal Fluid are Associated with Cognitive Decline in Patients with Alzheimer's Disease | 2.7 | 87 | Citations (PDF) |
| 455 | Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study | 2.5 | 73 | Citations (PDF) |
| 456 | Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease | 2.5 | 104 | Citations (PDF) |
| 457 | Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum | 2.5 | 186 | Citations (PDF) |
| 458 | Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer’s disease | 3.6 | 67 | Citations (PDF) |
| 459 | Monte Carlo feature selection and rule-based models to predict Alzheimer’s disease in mild cognitive impairment | 3.6 | 12 | Citations (PDF) |
| 460 | Leukocyte Telomere Length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's Disease: A pilot study | 3.8 | 43 | Citations (PDF) |
| 461 | Aβ1-15/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases | 3.7 | 12 | Citations (PDF) |
| 462 | CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease | 2.5 | 211 | Citations (PDF) |
| 463 | No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease | 2.5 | 35 | Citations (PDF) |
| 464 | Evaluation of GeneMapper®ID-X Mixture Analysis tool | 0.5 | 4 | Citations (PDF) |
| 465 | Antihypertensive Therapy Is Associated with Reduced Rate of Conversion to Alzheimer's Disease in Midregional Proatrial Natriuretic Peptide Stratified Subjects with Mild Cognitive Impairment | 1.7 | 22 | Citations (PDF) |
| 466 | Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases | 4.1 | 73 | Citations (PDF) |
| 467 | Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls | 2.7 | 68 | Citations (PDF) |
| 468 | Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population | 2.7 | 58 | Citations (PDF) |
| 469 | Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women | 2.5 | 8 | Citations (PDF) |
| 470 | Cerebrospinal Fluid Microglial Markers in Alzheimer’s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility | 3.7 | 97 | Citations (PDF) |
| 471 | Prediction of Alzheimer’s Disease Using Midregional Proadrenomedullin and Midregional Proatrial Natriuretic Peptide | 2.9 | 27 | Citations (PDF) |
| 472 | Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years | 2.7 | 103 | Citations (PDF) |
| 473 | Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease | 2.5 | 171 | Citations (PDF) |
| 474 | Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity | 2.4 | 107 | Citations (PDF) |
| 475 | Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease | 14.2 | 77 | Citations (PDF) |
| 476 | Cystatin C Levels are Positively Correlated with both Aβ42 and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls | 2.7 | 24 | Citations (PDF) |
| 477 | Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain | 2.7 | 19 | Citations (PDF) |
| 478 | Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults | 6.8 | 93 | Citations (PDF) |
| 479 | Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People | 6.8 | 384 | Citations (PDF) |
| 480 | Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years | 3.4 | 86 | Citations (PDF) |
| 481 | Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment | 3.4 | 236 | Citations (PDF) |
| 482 | Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment | 3.4 | 2 | Citations (PDF) |
| 483 | Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment | 3.4 | 94 | Citations (PDF) |
| 484 | CSF biomarkers predict a more malignant outcome in Alzheimer disease | 1.3 | 173 | Citations (PDF) |
| 485 | A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease | 6.7 | 27 | Citations (PDF) |
| 486 | Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease | 6.7 | 78 | Citations (PDF) |
| 487 | Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease | 2.5 | 89 | Citations (PDF) |
| 488 | Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests | 2.4 | 67 | Citations (PDF) |
| 489 | Evolution of Aβ42 and Aβ40 levels and Aβ42/Aβ40 ratio in plasma during progression of Alzheimer's disease: A multicenter assessment | 3.1 | 45 | Citations (PDF) |
| 490 | Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease | 3.4 | 63 | Citations (PDF) |
| 491 | CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies | 3.4 | 43 | Citations (PDF) |
| 492 | Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease | 1.9 | 31 | Citations (PDF) |
| 493 | Interleukin-6 Is Elevated in the Cerebrospinal Fluid of Suicide Attempters and Related to Symptom Severity | 1.7 | 435 | Citations (PDF) |
| 494 | Trace DNA collection—Performance of minitape and three different swabs | 0.5 | 51 | Citations (PDF) |
| 495 | CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment | 13.7 | 928 | Citations (PDF) |
| 496 | Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease | 2.5 | 77 | Citations (PDF) |
| 497 | A fast analysis system for forensic DNA reference samples | 2.4 | 21 | Citations (PDF) |
| 498 | A comparison of three automated DNA purification methods in Forensic casework | 0.5 | 11 | Citations (PDF) |
| 499 | Automatic data processing of reference DNA-profiles from FTA and non-FTA samples | 0.5 | 1 | Citations (PDF) |
| 500 | Proteinase K challenged by a novel protease | 0.5 | 1 | Citations (PDF) |
| 501 | Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease | 6.8 | 184 | Citations (PDF) |
| 502 | Novel Panel of Cerebrospinal Fluid Biomarkers for the Prediction of Progression to Alzheimer Dementia in Patients With Mild Cognitive Impairment | 6.8 | 115 | Citations (PDF) |
| 503 | Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease | 4.1 | 6 | Citations (PDF) |
| 504 | Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study | 19.1 | 1,341 | Citations (PDF) |
| 505 | Overexpression of heat shock protein 70 in R6/2 Huntington’s disease mice has only modest effects on disease progression | 2.5 | 109 | Citations (PDF) |
| 506 | Cyclosporin A and Bcl-2 do not inhibit quinolinic acid-induced striatal excitotoxicity in rodents | 4.1 | 10 | Citations (PDF) |
| 507 | Lack of neuroprotection by heat shock protein 70 overexpression in a mouse model of global cerebral ischemia | 1.4 | 35 | Citations (PDF) |
| 508 | Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease | 12.8 | 514 | Citations (PDF) |
| 509 | Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length | 4.0 | 48 | Citations (PDF) |
| 510 | Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine | 3.7 | 36 | Citations (PDF) |
| 511 | Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene | 3.7 | 131 | Citations (PDF) |
| 512 | Improving the Survival of Grafted Dopaminergic Neurons: A Review over Current Approaches | 2.8 | 308 | Citations (PDF) |
| 513 | Grafting of Nigral Tissue Hibernated with Tirilazad Mesylate and Glial Cell Line-Derived Neurotrophic Factor | 2.8 | 17 | Citations (PDF) |
| 514 | Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured striatal neurons | 2.5 | 88 | Citations (PDF) |
| 515 | Chapter 10 Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease | 0.0 | 34 | Citations (PDF) |
| 516 | FK506 and Cyclosporin A Enhance the Survival of Cultured and Grafted Rat Embryonic Dopamine Neurons | 4.1 | 43 | Citations (PDF) |
| 517 | Additive Effects of Caspase Inhibitor and Lazaroid on the Survival of Transplanted Rat and Human Embryonic Dopamine Neurons | 4.1 | 80 | Citations (PDF) |
| 518 | Caspase inhibition reduces apoptosis and increases survival of nigral transplants | 25.6 | 257 | Citations (PDF) |
| 519 | Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity | 7.7 | 207 | Citations (PDF) |
| 520 | Flunarizine improves the survival of grafted dopaminergic neurons | 2.5 | 35 | Citations (PDF) |
| 521 | Patterns of Cell Death and Dopaminergic Neuron Survival in Intrastriatal Nigral Grafts | 4.1 | 87 | Citations (PDF) |
| 522 | Neuronal death in nigral grafts in the absence of poly (ADP-ribose) polymerase activation | 1.5 | 9 | Citations (PDF) |
| 523 | Mitochondrial Control of Acute Glutamate Excitotoxicity in Cultured Cerebellar Granule Cells | 3.7 | 181 | Citations (PDF) |
| 524 | Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity | 1.6 | 59 | Citations (PDF) |
